Biopharma financing rebounded in Q1 2026, with total financings reaching $22.82 billion—about 74% higher than Q1 2025—after a weaker 2025. The figures suggest improved access to capital for biotech and med-tech sponsors, even though overall funding remains below earlier peak years. The data align with broader capital-market activity referenced elsewhere in the dataset, including ongoing fundraising and deal momentum across emerging modalities. For biotech teams, the improved Q1 pace can affect timing decisions for clinical milestones and investor communications. Market participants will likely track whether the rebound sustains into Q2, particularly for earlier-stage and platform-heavy companies that depend on continued risk appetite.